On October 22, 2019 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, reported that it will participate in the Jefferies 2019 London Healthcare Conference on November 20 & 21 in London (United Kingdom) (Press release, Transgene, OCT 22, 2019, View Source [SID1234542417]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The management will meet with leading European Healthcare investors to present its innovative immunotherapy portfolio and detail the promising clinical results obtained with the combination regimen of TG4001 in HPV-positive cancers.